Use Salix Pharmaceuticals Ltd management performance together with your other stock asset holdings to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences. Optimize Portfolio
Salix Management Effectiveness
The company has return on total asset (ROA) of 7.24 % which means that it generated profit of $7.24 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 11.57 % meaning that it created $11.57 on every $100 dollars invested by stockholders.
The company has Profit Margin (PM) of 8.74 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 25.03 % which suggests for every 100 dollars of sales it generated a net operating income of 0.25.
Salix Pharmaceuticals Ltd is rated fourth in number of employees category among related companies. The total workforce of Drugs - Generic industry is at this time estimated at about 22,848. Salix holds roughly 525 in number of employees claiming about 2.3% of equities under Drugs - Generic industry.
CEO and President Director and Member of Pricing Committee
Ms. Carolyn J. Logan is President, Chief Executive Officer, Director of Salix Pharmaceuticals, Ltd. She previously served as Senior Vice President, Sales and Marketing from June 2000 to July 2002. ...
Mr. Thomas W. D'Alonzo is Independent Chairman of the Board of Salix Pharmaceuticals, Ltd. He has served as a member of Board of Directors since May 2000 and was the Chairman of the Board since June 2010. ...
Salix employes about 525 people. The company is managed by 12 executives with total tenure of roughly 53 years, averanging almost 4.0 years of service per executive having 43.0 employee per reported executive.
Return on Salix Manpower
Revenue Per Employee
1.4 M
Revenue Per Executive
61.3 M
Net Income Per Employee
122.4 K
Net Income Per Executive
5.4 M
Working Capital Per Employee
1.8 M
Working Capital Per Executive
77.3 M
Salix Earnings Per Share
According to company disclosure Salix Pharmaceuticals Ltd has Earnings Per Share of 1.01 times. This is 46.56% lower than that of Healthcare sector, and 81.37% lower than that of Drugs - Generic industry, The Earnings Per Share for all stocks is 44.81% higher than the company.
Earnings per Share is one of the most important measures of current share price of a firm, and is used by investors to determine company overall profitability especially when it is compared to EPS of similar companies.
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated.
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory
1.03%
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
